In contrast to ADCs in which no significant additive effect was observed, our results show that, in squamous NSCLC, carboplatin + paclitaxel chemotherapy combined with targeted therapies directed against MAPK and PI3K pathways, or CDK4/6, were significantly more efficient than each treatment tested alone. This evidence concerns the gene CDK4 and non-small cell lung carcinoma.